Main Article Content

Ahana Bhaduri Adrija Bose Mukesh Singh Suvroma Gupta


Extensive research is being conducted for cancer treatment but eradicating cancer cells is a great challenge till date due to lack of understanding regarding cancer development and manifestation in the systemic and local environment. L-asparaginase (ASNase), a well-known drug since decades for treatment of paediatric Acute Lymphoblastic Leukemia (ALL) is an enzyme that restricts the ability of the non-essential amino acid asparagine for tumor progression by breaking it down to aspartic acid and ammonia thereby depriving tumor cells from their key nutrient for survival. Though the enzyme has gained immense interest in clinical and scientific community the major challenge posed by the use of this specific enzyme in antilymphoproliferative studies is the induction of several immunogenic responses. In this review, we have highlighted the different encapsulation techniques using emerging carrier molecules to increase enzyme efficacy with a minimum negative impact on the living cells. Further we have highlighted the recent approach in which encapsulation of the enzyme using diverse nanoparticles which have proved its effectiveness in rendering target-specific action along with reduced immunogenicity, improved half-life, thermal stability and better enzyme activity.

Article Details


Afrin F., Rajesh R., Anam K., Gopinath M., Pal S., Ali N. Characterization of Leishmania donovani antigens encapsulated in liposomes that induce protective immunity in BALB/c mice. Infection and Immunity, 2002, 70(12): 6697-6706.

Agrawal S., Sharma I., Prajapati B.P., Suryawanshi R.K., Kango N. Catalytic characteristics and application of ASNase immobilized on aluminium oxide pellets. International Journal of Biological Macromolecules, 2018,114(8): 504-511.

Ahmadpour S., Hosseinimehr S. PASylation as a powerful technology for improving the pharmacokinetic properties of biopharmaceuticals. Current Drug Delivery. 2018, 15(3): 331-341.

Armstrong J.K. Antibody against poly (ethylene glycol) adversely affects PEG-asparaginase therapy in acute lymphoblastic leukemia patients. Cancer, 2007, 110(1):103-111.

Asselin B., Rizzari C. Asparaginase pharmacokinetics and implications of therapeutic drug monitoring. Leukemia & Lymphoma. 2015, 56(8): 2273-2280.

Ates B., Ulu A., Köytepe S., Noma S.A.A., Kolat V.S., Izgi T. Magnetic-propelled Fe3O4–chitosan carriers enhance ASNase catalytic activity: a promising strategy for enzyme immobilization. RSC Advances. 2018, 8(63): 36063-36075.

Avramis V.I., Avramis E.V., Hunter W., Long M.C. Immunogenicity of native or PEGylated E. coli and Erwinia asparaginases assessed by ELISA and surface plasmon resonance (SPR-biacore) assays of IgG antibodies (Ab) in sera from patients with acute lymphoblastic leukemia (ALL). Anticancer Research. 2009, 29(1): 299-302. Available at:

Avramis V.I., Sencer S., Periclou A.P., Sather H., Bostrom B.C., Cohen L.J., Ettinger A.G., Ettinger L.J., Franklin J., Gaynon P.S., Hilden J.M., Lange B., Majlessipour F., Mathew P., Needle M., Neglia J., Reaman G., Holcenberg J.S. A randomized comparison of native Escherichia coli asparaginase and polyethylene glycol conjugated asparaginase for treatment of children with newly diagnosed standard-risk acute lymphoblastic leukemia: a Children's Cancer Group study. Blood, 2002, 99(6): 1986-1994.

Avramis V.I., Tiwari P.N. Asparaginase (native ASNase or pegylated ASNase) in the treatment of acute lymphoblastic leukemia. International Journal of Nanomedicine, 2006, 1(3): 241-254. Available at:

Bahraman F., Alemzadeh I. Optimization of ASNase immobilization onto calcium alginate beads. Chemical Engineering Communications, 2017, 204(2): 216-220.

Bailon P., Berthold W. Polyethylene glycol-conjugated pharmaceutical proteins. Pharmaceutical Science & Technology Today, 1998, 1(8): 352-356.

Baran E.T., Hasirci V.J. In vivo half-life of nanoencapsulated ASNase. Journal of Materials Science: Materials in Medicine, 2002, 13(12): 1113-1121.

Barros R.A.M., Cristóvão R.O., Carabineiro S.A.C., Neves M.C., Freire M.G., Faria J.L., Santos-Ebinuma V.C., Tavares A.P.M., Silva C.G. Immobilization and characterization of L-asparaginase over carbon xerogels. BioTech (Basel), 2022,11(2): 10.

Blackman L.D., Varlas S., Arno M.C., Houston Z.H., Fletcher N.L., Thurecht K.J., Hasan M., Gibson M.I., O’Reilly R.K. Confinement of therapeutic enzymes in selectively permeable polymer vesicles by polymerization-induced self-assembly (PISA) reduces antibody binding and proteolytic susceptibility. ACS Central Science, 2018, 4(6): 718-723.

Bodmer M., Sulz M., Stadlmann S., Droll A., Terracciano L., Krähenbühl S. Fatal liver failure in an adult patient with acute lymphoblastic leukemia following treatment with ASNase. Digestion, 2006, 74(1): 28-32.

Boos J., Werber G., Ahlke E., Schulze-Westhoff P., Nowak-Göttl U., Würthwein G., Verspohl E.J., Ritter J., Jürgens H. Monitoring of asparaginase activity and asparagine levels in children on different asparaginase preparations. European Journal of Cancer. 1996, 32(9): 1544-1550.

Bowen S., Tare N., Inoue T., Yamasaki M., Okabe M., Horii I., Eliason J.F. Relationship between molecular mass and duration of activity of polyethylene glycol conjugated granulocyte colony-stimulating factor mutein. Experimental Hematology, 1999, 27(3): 425-432.

Broome J.D. Evidence that the ASNase of guinea pig serum is responsible for its antilymphoma effects: I. Properties of the ASNase of guinea pig serum in relation to those of the antilymphoma substance. Journal of Experimental Medicine, 1963, 118(1): 99-120.

Brumano L.P., da Silva F.V.S., Costa-Silva T.A., Apolinário A.C., Santos J.H.P.M., Kleingesinds E.K., Monteiro G., Rangel-Yagui C.O., Benyahia B., Pessoa Junior A.Development of ASNasebiobetters: current research status and review of the desirable quality profiles. Frontiers in Bioengineering and Biotechnology, 2019, 6(1): 212.

Chiu M., Taurino G., Bianchi M.G., Kilberg M.S., Bussolati O. Asparagine synthetase in cancer: beyond acute lymphoblastic leukemia. Frontiers in Oncology, 2019, 9(1): 01480.

Chow Y.., Ting A.S.Y. Endophytic ASNase-producing fungi from plants associated with anticancer properties. Journal of Advanced Research, 2015, 6(6): 869-876.

Debnath S., Kumar R.S., Babu M.N. Ionotropic gelation - a novel method to prepare chitosan nanoparticles. Research Journal of Pharmacy and Technology, 2011, 4(4): 492-495. Available at:

Duval M., Suciu S., Ferster A., Rialland X., Nelken B., Lutz P., Benoit Y., Robert A., Manel A.-M., Vilmer E., Otten J., Philippe N. Comparison of Escherichia coli–asparaginase with Erwinia-asparaginase in the treatment of childhood lymphoid malignancies: results of a randomized European Organisation for Research and Treatment of Cancer-Children's Leukemia Group phase 3 trial. Blood, 2002, 99(8): 2734-2739.

Fernandes A.I., Gregoriadis G. Polysialylated asparaginase: preparation, activity and pharmacokinetics. Biochimica et Biophysica Acta (BBA) - Protein Structure and Molecular Enzymology, 1997, 1341(1): 26-34.

Fromenty B., Pessayre D. Impaired mitochondrial function in microvesicular steatosis effects of drugs, ethanol, hormones and cytokines. Journal of Hepatology, 1997, 26(Suppl. 2): 43-53.

Fromenty B., Pessayre D. Inhibition of mitochondrial beta-oxidation as a mechanism of hepatotoxicity. Pharmacology & Therapeutics, 1995, 67(1): 101-154.

Gabizon A., Martin F. Polyethylene glycol-coated (pegylated) liposomal doxorubicin. Drugs, 1997, 54(4): 15-21.

Garay R.P., El-Gewely R., Armstrong J.K., Garratty G., Richette P. Antibodies against polyethylene glycol in healthy subjects and in patients treated with PEG-conjugated agents. Expert Opinion on Drug Delivery, 9(11): 1319-1323.

Ghosh S., Chaganti S.R., Prakasham R.S. Polyaniline nanofiber as a novel immobilization matrix for the anti-leukemia enzyme ASNase. Journal of Molecular Catalysis B: Enzymatic, 2012, 74(1-2): 132-137.

Golestaneh D., Varshosaz J. Enhancement in biological activity of L-asparginase by its conjugation on silica nanoparticles. Recent Patents on Nanotechnology, 2018, 12(1): 70-82.

Göpel W., Schnetzke U., Hochhaus A., Scholl S. Functional acute liver failure after treatment with pegylated asparaginase in a patient with acute lymphoblastic leukemia: potential impact of plasmapheresis. Annals of Hematology, 2016, 95(11): 1899-1901.

Harrington K.J., Mohammadtaghi S., Uster P.S., Glass D., Peters A.M., Vile R.G., Stewart J.S.W. Effective targeting of solid tumors in patients with locally advanced cancers by radiolabeled PEGylated liposomes. Clinical Cancer Research, 2001, 7(2): 243-254. Available at:

Hashimoto Y., Shimizu T., Mima Y., Lila A.S.A., Ishida T., Kiwada H. Generation, characterization and in vivo biological activity of two distinct monoclonal anti-PEG IgMs. Toxicology and Applied Pharmacology, 2014, 277(1): 30-38.

Heitink-Pollé K.M., Prinsen B.H., de Koning T.J., van Hasselt P.M., Bierings M.B. High incidence of symptomatic hyperammonemia in children with acute lymphoblastic leukemia receiving PEGylated asparaginase. JIMD Reports - Case and Research Reports, 2012, 7(4): 103-108.

Heo Y.A., Syed Y.Y., Keam S.J. Pegaspargase: A review in acute lymphoblastic leukaemia. Drugs, 2019, 79(7): 767-777.

Hettmer S., Schinzel A.C., Tchessalova D., Schneider M., Parker C.L., Bronson R.T, Richards N.G.J., Hahn W.C., Wagers A.J. Functional genomic screening reveals asparagine dependence as a metabolic vulnerability in sarcoma. eLife, 2015, 4(10): e09436.

Jaccard A., Petit B., Girault S., Suarez F., Gressin R., Zini J.-M., Coiteux V., Larroche C., Devidas A., Thiéblemont C., Gaulard P., Marin B., Gachard N., Bordessoule D., Hermine O. ASNase-based treatment of 15 western patients with extranodal NK/T-cell lymphoma and leukemia and a review of the literature. Annals of Oncology, 2009, 20(1): 110-116.

Jean-François J., Fortier G. Immobilization of L‐asparaginase into a biocompatible poly (ethylene glycol) ‐ albumin hydrogel: I: Preparation and in vitro characterization. Biotechnology and Applied Biochemistry, 1996, 23(3): 221-226. or

Jevševar S., Kunstelj M., Porekar V.G. PEGylation of therapeutic proteins. Biotechnology Journal, 2010, 5(1): 113-128.

Karsakevich A.S., Vina I.A., Liduma G.Y. Immobilization of the enzyme E. coli ASNase on a water-soluble copolymer of vinylpyrrolidone and acrolein. Chemistry of Natural Compounds, 1988, 24(4): 477-480.

Katas H., Raja M.A.G., Lam K.L. Development of chitosan nanoparticles as a stable drug delivery system for protein/siRNA. International Journal of Biomaterials, 2013, 2013(9): 146320.

Kidd J.G. Regression of transplanted lymphomas induced in vivo by means of normal guinea pig serum: I. course of transplanted cancers of various kinds in mice and rats given guinea pig serum, horse serum, or rabbit serum. Journal of Experimental Medicine, 1953, 98(6): 565-582.

Kolev N. Natural antioxidants - an alternative for reduction of nitrites in cooked meat products. Food Science and Applied Biotechnology, 2022, 5(1): 64-76.

Kozlowski A., Harris J.M. Improvements in protein PEGylation: PEGylated interferons for treatment of hepatitis C. Journal of Controlled Release, 2001, 72(1-3): 217-224.

Konhäuser M., Kannaujiya V.K., Steiert E., Schwickert K., Schirmeister T., Wich P.R. Co-encapsulation of l-asparaginase and etoposide in dextran nanoparticles for synergistic effect in chronic myeloid leukemia cells, International Journal of Pharmaceutics, 2022, 622(6): 121796.

Kotzia G.A., Lappa K., Labrou N.E. Tailoring structure-function properties of Lasparaginase: engineering resistance to trypsin cleavage. Biochemical Journal, 2007, 404(2): 337-343.

Krall A.S., Xu S., Graeber T.G., Braas D., Christofk H. Asparagine promotes cancer cell proliferation through use as an amino acid exchange factor. Nature Communications, 2016, 7(1): 1-13.

Lanvers-Kaminsky C., Niemann A., Eveslage M., Beck J., Köhnke T., Martin S., de Wit M., Spriewald B., Hauspurg H., Hoelzer D., Boos J., Gökbuget N. Asparaginase activities during intensified treatment with pegylated E. coli asparaginase in adults with newly-diagnosed acute lymphoblastic leukemia. Leukemia & Lymphoma, 2020, 61(1): 138-145.

Lanvers-Kaminsky C. Asparaginase pharmacology: challenges still to be faced. Cancer Chemotherapy and Pharmacology, 2017, 79(3): 439-450.

Liu C., Kawedia J.D., Cheng C., Pei D., Fernandez C.A., Cai X., Crews K.R., Kaste S.C., Panetta J.C., Bowman W.P., Jeha S., Sandlund J.T., Evans W.E., Pui C.-H., Relling M.V. Clinical utility and implications of asparaginase antibodies in acute lymphoblastic leukemia. Leukemia, 2012, 26(11): 2303-2309.

Maysa E.M., Amira M., Gamal E., Sanaa T., Sayed E. Production, immobilization and anti-tumor activity of ASNase of Bacillus sp R36. Journal of American Science, 2010, 6(8): 157-165. Available at:

Mehvar R. Modulation of the pharmacokinetics and pharmacodynamics of proteins by polyethylene glycol conjugation. Journal of Pharmaceutical Sciences, 2000, 3(1): 125-136. Available at:

Melik-Nubarov N.S., Grozdova I.D., Lomakina G.Y., Pokrovskaya M.V., Pokrovski V.S., Aleksandrova S.S., Abakumova O.Yu., Podobed O.V., Grishin D.V., Sokolov N.N. PEGylated recombinant ASNase from Erwinia carotovora: Production, properties, and potential applications. Applied Biochemistry and Microbiology, 2017, 53(2): 165-172.

Meneguetti G.P., Santos J.H.P.M., Obreque K.M.T., Barbosa C.M.V., Monteiro G., Farsky S.H.P., de Oliveira A.M., Angeli C.B., Palmisano G., Ventura S.P.M., Pessoa-Junior A., Rangel-Yagui C.O. Novel site-specific PEGylated ASNase. PLoS One, 2019, 14(2): e0211951.

Milla P., Dosio F., Cattel L. PEGylation of proteins and liposomes: a powerful and flexible strategy to improve the drug delivery. Current Drug Metabolism. 2012, 13(1): 105-119.

Mishra P., Nayak B., Dey R.K. PEGylation in anti-cancer therapy: An overview. Asian Journal of Pharmaceutical Sciences, 2016, 11(3): 337-348.

Molineux G., Kinstler O., Briddell B., Hartley C., McElroy P., Kerzic P., W. Sutherland, G. Stoney, B. Kern, Fletcher F.A., Cohen A., Korach E., Ulich T., McNiece I., Lockbaum P., Miller-Messana M.A., Gardner S., Hunt T., Schwab G. A new form of Filgrastim with sustained duration in vivo and enhanced ability to mobilize PBPC in both mice and humans. Experimental Hematology, 1999, 27(12): 1724-1734.

Molineux G. Pegylation: engineering improved pharmaceuticals for enhanced therapy. Cancer Treatment Reviews, 2002, 28(Suppl. 1): 13-16.

Mori T., Tosa T., Chibata I. Preparation and properties of asparaginase entrapped in the lattice of polyacrylamide gel. Cancer Research, 1974, 34(11): 3066-3068. Available at:

Nadumane V.K., Venkatachalam P., Gajaraj B. Chapter 19 - Aspergillus Applications in Cancer Research. In: New and Future Developments in Microbial Biotechnology and Bioengineering. Aspergillus System Properties and Applications (V.K. Gupta Ed.), Elsevier B.V. 2016, pp. 243-255. ISBN: 978-0-444-63505-1

Narta U.K., Kanwar S.S., Azmi W. Pharmacological and clinical evaluation of ASNase in the treatment of leukemia. Critical Reviews in Oncology/Hematology, 2007, 61(3): 208-221.

Noma S.A.A., Acet O., Ulu A., Önal B., Odabaşı M., Ateş B. L-asparaginase immobilized p(HEMA-GMA) cryogels: A recent study for biochemical, thermodynamic and kinetic parameters, Polymer Testing, 2021, 93(1): 106980.

Nowak-Göttl U., Heinecke A., von Kries R., Nürnberger W., Münchow N., Junker R. Thrombotic events revisited in children with acute lymphoblastic leukemia: impact of concomitant Escherichia coli asparaginase/prednisone administration. Thrombosis Research, 2001, 103(3): 165-172.

Orhan H., Uygun D.A. Immobilization of ASNase on magnetic nanoparticles for cancer treatment. Applied Biochemistry and Biotechnology, 2020, 1-12.

Panosyan E.H., Seibel N.L., Martin-Aragon S., Gaynon P.S., Avramis I.A., Sather H., Franklin J., Nachman J., Ettinger L.J., La M., Steinherz P., Cohen L.J., Siegel S.E., Avramis V.I. Asparaginase antibody and asparaginase activity in children with higher-risk acute lymphoblastic leukemia: Children's Cancer Group Study CCG-1961. Journal of Pediatric Hematology/Oncology, 2004, 26(4): 217-226.

Patel N., Krishnan S., Offman M.N., Krol M., Moss C.X., Leighton C., van Delft F.W., Holland M., Liu J.Z., Alexander S., Dempsey C., Ariffin H., Essink M., Eden T.O.B., Watts C., Bates P.A., Saha V. A dyad of lymphoblastic lysosomal cysteine proteases degrades the antileukemic drug ASNase. The Journal of Clinical Investigation, 2009, 119(7): 1964-1973.

Piatkowska-Jakubas B., Krawczyk-Kuliś M., Giebel S., Adamczyk-Cioch M., Czyz A., Marańda E.L., Paluszewska M., Pałynyczko G., Piszcz J., Hołowiecki J. Use of ASNase in acute lymphoblastic leukemia: recommendations of the Polish Adult Leukemia Group. Polish Archives of Internal Medicine, 2008, 118(11): 664-669.

Place A.E., Stevenson K.E., Vrooman L.M., Harris M.H., Hunt S.K., O'Brien J.E., Supko J.G., Asselin B.L., Athale U.H., Clavell L.A., Cole P.D., Kelly K.M., Laverdiere C., Leclerc J.-M., Michon B., Schorin M.A., Welch J.J.G., Lipshultz S.E., Kutok J.L., Blonquist T.M., Neuberg D.S., Sallan S.E., Silverman L.B. Intravenous pegylated asparaginase versus intramuscular native Escherichia coli ASNase in newly diagnosed childhood acute lymphoblastic leukaemia (DFCI 05-001): a randomised, open-label phase 3 trial. The Lancet Oncology, 2015, 16(16): 1677-1690.

Poppenborg S.M., Wittmann J., Walther W., Brandenburg G., Krähmer R., Baumgart J., Leenders F. Impact of anti-PEG IgM antibodies on the pharmacokinetics of PEGylated asparaginase preparations in mice. European Journal of Pharmaceutical Sciences, 2016, 91(8): 122-130.

Poznansky M.J., Shandling M., Salkie M.A., Elliott J., Lau E. Advantages in the use of ASNase-albumin polymer as an antitumor agent. Cancer Research, 1982, 42(3): 1020-1025.

Qian G., Ma J., Zhou J., He B. The chemical modification of E. coli ASNase with poly (N-vinylpyffolidone-co-maleic anhydride). Artificial Cells, Blood Substitutes, and Biotechnology, 1996, 24(6): 567-577.

Raja R.A., Schmiegelow K., Frandsen T.L. Asparaginase‐associated pancreatitis in children. British Journal of Haematology, 2012, 159(1): 18-27.

Ramirez-Paz J., Saxena M., Delinois L.J., Joaquín-Ovalle F.M., Lin S., Chen Z., Rojas-Nieves V.A., Griebenow K. Thiol-maleimide poly (ethylene glycol) crosslinking of L-asparaginase subunits at recombinant cysteine residues introduced by mutagenesis. Plos ONE, 2018, 2018(8): 0197643.

Ravera E, Martelli T, Geiger Y, Fragai M, Goobes G, Luchinat C. Biosilica and bioinspired silica studied by solid-state NMR. Coordination Chemistry Reviews. 2016, 327-328(11): 110-122.

Rodríguez‐Martínez J.A., Solá R.J., Castillo B., Cintrón‐Colón H.R., Rivera‐Rivera I., Barletta G., Griebenow K. Stabilization of α‐chymotrypsin upon PEGylation correlates with reduced structural dynamics. Biotechnology & Bioengineering, 2008, 101(6): 1142-1149.

Saeed R.M., Dmour I., Taha M.O. Stable chitosan-based nanoparticles using polyphosphoric acid or hexametaphosphate for tandem ionotropic/covalent crosslinking and subsequent investigation as novel vehicles for drug delivery. Frontiers in Bioengineering and Biotechnology, 2020, 8(1): 00004.

Safary A., Moniri R., Hamzeh-Mivehroud M., Dastmalchi S. Highly efficient novel recombinant ASNase with no glutaminase activity from a new halo-thermotolerant Bacillus strain. BioImpacts, 2019, 9(1): 15-23.

Sarbassov D.D., Ali S.M., Sabatini D.M. Growing roles for the mTOR pathway. Current Opinion in Cell Biology, 2005, 17(6): 596-603.

Sharma G., Rath G., Goyal A. Improved biological activity and stability of enzyme ASNase in solid lipid nanoparticles formulation. Journal of Drug Delivery and Therapeutics, 2019, 9(2-s): 325-329.

Shaunak S., Godwin A., Choi J.-W., Balan S., Pedone E., Vijayarangam D., Heidelberger S., Teo I., Zloh M., Brocchini S. Site-specific PEGylation of native disulfide bonds in therapeutic proteins. Nature Chemical Biology, 2006, 2(6): 312-313.

Shinnick S.E., Browning M.L., Koontz S. Managing hypersensitivity to asparaginase in pediatrics, adolescents, and young adults. Journal of Pediatric Hematology/Oncology Nursing, 2013, 30(2): 63-77.

Shrivastava A, Khan AA, Khurshid M, Kalam MA, Jain SK, Singhal PK. Recent developments in ASNase discovery and its potential as anticancer agent. Critical Reviews in Oncology/Hematology, 2016, 100(4): 1-10.

Sukhoverkov K.V., Kudryashova E.V. PEG-chitosan and glycol-chitosan for improvement of biopharmaceutical properties of recombinant ASNase from Erwinia carotovora. Biochemistry (Moscow), 2015, 80(1): 113-119.

Ulu A., Koytepe S., Ates B. Synthesis and characterization of PMMA composites activated with starch for immobilization of L‐asparaginase. Journal of Applied Polymer Science, 2016, 133(19): 43421.

Ulu A., Noma S.A., Koytepe S., Ates B. Magnetic Fe3O4@MCM-41 core–shell nanoparticles functionalized with thiol silane for efficient ASNase immobilization. Artificial Cells, Nanomedicine, and Biotechnology, 2018, 46(Suppl. 2): 1035-1045.

Van den Berg H. Asparaginase revisited. Leukemia & Lymphoma, 2011, 52(2): 168-178.

Veronese F.M., Caliceti P., Schiavon O. Branched and linear poly (ethylene glycol): Influence of the polymer structure on enzymological, pharmacokinetic, and immunological properties of protein conjugates. Journal of Bioactive and Compatible Polymers, 1997, 12(3): 196-207.

Veronese F.M., Mero A. The impact of PEGylation on biological therapies. BioDrugs, 2008, 22(5): 315-329.

Veronese F.M., Monfardini C., Caliceti P., Schiavon O., Scrawen M.D., Beer D. Improvement of pharmacokinetic, immunological and stability properties of asparaginase by conjugation to linear and branched monomethoxy poly (ethylene glycol). Journal of Controlled Release, 1996, 40(3): 199-209.

Veronese F.M. Peptide and protein PEGylation: a review of problems and solutions. Biomaterials. 2001, 22(5): 405-417.

Vidya J., Sajitha S., Ushasree M.V., Sindhu R., Binod P., Madhavan A., Pandey A. Genetic and metabolic engineering approaches for the production and delivery of ASNases: An overview. Bioresource Technology, 2017, 245. Part B(12): 1775-1781.

Vieira Pinheiro J.P., Ahlke E., Nowak‐Göttl U., Hempel G., Müller H.J., Lümkemann K., Schrappe M., Rath B., Fleischhack G., Mann G., Boos J. Pharmacokinetic dose adjustment of Erwinia asparaginase in protocol II of the paediatric ALL/NHL‐BFM treatment protocols. British Journal of Haematology, 1999, 104(2): 313-320.

Villanueva-Flores F., Zárate-Romero A., Torres A.G., Huerta-Saquero A. Encapsulation of asparaginase as a promising strategy to improve in vivo drug performance. Pharmaceutics, 2021, 13(11): 1965.

Vrooman L.M., Supko J.G., Neuberg D.S., Asselin B.L., Athale U.H., Clavell L., Kelly K.M., Laverdière C., Michon B., Schorin M., Cohen H.J., Sallan S.E., Silverman L.B. See fewer authors. Erwinia asparaginase after allergy to E. coli asparaginase in children with acute lymphoblastic leukemia. Pediatric Blood & Cancer, 2010, 54(2): 199-205.

Wileman T.E., Foster R.L., Elliott P.N.C. Soluble asparaginase‐dextran conjugates show increased circulatory persistence and lowered antigen reactivity. Journal of Pharmacy and Pharmacology, 1986, 38(4): 264-271.

Yamaguchi M., Suzuki R., Kwong Y.L., Kim W.S., Hasegawa Y., Izutsu K., Suzumiya J., Okamura T., Nakamura S., Kawa K., Oshimi K. Phase I study of dexamethasone, methotrexate, ifosfamide, l‐asparaginase, and etoposide (SMILE) chemotherapy for advanced‐stage, relapsed or refractory extranodal natural killer (NK)/T‐cell lymphoma and leukemia. Cancer Science (formerly Japanese Journal of Cancer Research), 2008, 99(5): 1016-1020.

Yong W., Zheng W., Zhang Y., Zhu J., Wei Y., Zhu D., Li J. ASNase-based regimen in the treatment of refractory midline nasal/nasal-type T/NK-cell lymphoma. International Journal of Hematology, 2003, 78(2): 163-167.

Youssef M.M., Al-Omair M.A. Cloning, purification, characterization and immobilization of ASNase II from E. coli W3110. Asian Journal of Biochemistry, 2008, 3(6): 337-350.

Zhang C., Yang X.l., Yuan Y.H., Pu J., Liao F. Site-specific PEGylation of therapeutic proteins via optimization of both accessible reactive amino acid residues and PEG derivatives. BioDrugs, 2012, 26(4): 209-215.

Zhang L., Liu Y., Liu G., Xu D., Liang S., Zhu X., Lu Y., Wang H. Prolonging the plasma circulation of proteins by nano-encapsulation with phosphorylcholine-based polymer. Nano Research, 2016, 9(8): 2424-2432.

How to Cite
BHADURI, Ahana et al. Conjugation and encapsulation of L-asparaginase: an effective strategy for augmenting enzyme potential for anticancer activity. Food Science and Applied Biotechnology, [S.l.], v. 6, n. 2, p. 339-356, oct. 2023. ISSN 2603-3380. Available at: <>. Date accessed: 21 may 2024. doi: